Immunohistochemical and molecular cytogenetic evaluation of potential targets for tyrosine kinase inhibitors in Langerhans cell histiocytosis.
暂无分享,去创建一个
T. Greiner | D. Weisenburger | W. Sanger | L. Medeiros | R. Miranda | L. Medeiros | P. Althof | G. Caponetti | Renae C Dobesh | Renae C. Dobesh
[1] J. Blay. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. , 2011, Cancer treatment reviews.
[2] A. Angelucci,et al. Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond. , 2011, Current medicinal chemistry.
[3] H. Ghofrani,et al. Targeting non-malignant disorders with tyrosine kinase inhibitors , 2010, Nature Reviews Drug Discovery.
[4] R. Egeler,et al. Langerhans cell histiocytosis: Current concepts and treatments. , 2010, Cancer treatment reviews.
[5] M. Yamakawa,et al. Differential immunophenotypic analysis of dendritic cell tumours , 2010, Journal of Clinical Pathology.
[6] C. Lome-Maldonado,et al. Gastrointestinal Langerhans cell histiocytosis responding to cladribine and imatinib mesylate , 2010 .
[7] J. Gotlib. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies , 2010, Current opinion in hematology.
[8] W. Sanger,et al. An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children’s Oncology Group study CCG‐5961 , 2010, British journal of haematology.
[9] A. Tefferi,et al. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. , 2010, Mayo Clinic proceedings.
[10] H. Kurzen,et al. Langerhans cell histiocytosis: treatment failure with imatinib. , 2009, Archives of dermatology.
[11] J. Piette,et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. , 2008, Blood.
[12] P. Chu,et al. Immunohistochemical Expression of Langerin in Langerhans Cell Histiocytosis and Non-Langerhans Cell Histiocytic Disorders , 2008, The American journal of surgical pathology.
[13] M. Rondoni,et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. , 2007, Blood.
[14] J. Utikal,et al. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. , 2007, Archives of dermatology.
[15] E. Scholar,et al. Role of Tyrosine Kinase Inhibitors in Cancer Therapy , 2005, Journal of Pharmacology and Experimental Therapeutics.
[16] Robert E. Brown. Brief communication: morphoproteomic analysis of osteolytic Langerhans cell histiocytosis with therapeutic implications. , 2005, Annals of clinical and laboratory science.
[17] R. Jaffe,et al. Langerin (CD207) Staining in Normal Pediatric Tissues, Reactive Lymph Nodes, and Childhood Histiocytic Disorders , 2004, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[18] L. Insabato,et al. Imatinib mesylate for cerebral Langerhans'-cell histiocytosis. , 2004, The New England journal of medicine.
[19] Peter Marynen,et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.
[20] G. Pinkus,et al. Langerhans cell histiocytosis immunohistochemical expression of fascin, a dendritic cell marker. , 2002, American journal of clinical pathology.
[21] R. Warnke,et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases , 2002, Histopathology.
[22] T. Colby,et al. Pulmonary Langerhans' Cell Histiocytosis: Molecular Analysis of Clonality , 2001, The American journal of surgical pathology.
[23] A. Kazlauskas,et al. Disruption of Gap Junctional Communication by the Platelet-derived Growth Factor Is Mediated via Multiple Signaling Pathways* , 1999, The Journal of Biological Chemistry.
[24] R. Arceci,et al. Controversies and new approaches to treatment of Langerhans cell histiocytosis. , 1998, Hematology/oncology clinics of North America.
[25] P. Gaulard,et al. Langerhans' cell histiocytosis. Definitive diagnosis with the use of monoclonal antibody O10 on routinely paraffin-embedded samples. , 1995, The American journal of surgical pathology.
[26] G. Cooper,et al. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. , 1995, Science.
[27] D. Gilliland,et al. Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. , 1994, The New England journal of medicine.
[28] L. Buluwela,et al. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis , 1994, The Lancet.
[29] L. Boumsell,et al. Immunohistochemical detection of cd1a antigen in formalin‐fixed and paraffin‐embedded tissue sections with monoclonal antibody 010 , 1993, The Journal of pathology.
[30] R. Ross,et al. The platelet-derived growth factor , 1978, Cell.
[31] M. Staufenbiel,et al. Amyloid beta-protein and apolipoprotein E co-localise within perivascular drainage channels in wild-type and APP-transgenic mice , 2006 .